Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Praxis Precision Medicines (PRAX) EBITDA Margin: 2023-2025

Historic EBITDA Margin for Praxis Precision Medicines (PRAX) over the last 3 years, with Sep 2025 value amounting to -1,770.82%.

  • Praxis Precision Medicines' EBITDA Margin rose 1704871.00% to -1,770.82% in Q3 2025 from the same period last year, while for Sep 2025 it was -1,316.76%, marking a year-over-year increase of 890225.00%. This contributed to the annual value of -2,340.29% for FY2024, which is 282412.00% up from last year.
  • Praxis Precision Medicines' EBITDA Margin amounted to -1,770.82% in Q3 2025, which was down 15.00% from -1,539.82% recorded in Q2 2025.
  • Praxis Precision Medicines' 5-year EBITDA Margin high stood at -856.97% for Q4 2024, and its period low was -18,819.54% during Q3 2024.
  • Its 3-year average for EBITDA Margin is -5,953.34%, with a median of -5,399.22% in 2023.
  • In the last 5 years, Praxis Precision Medicines' EBITDA Margin slumped by 1,336,740bps in 2024 and then soared by 1,704,871bps in 2025.
  • Praxis Precision Medicines' EBITDA Margin (Quarterly) stood at -5,399.22% in 2023, then skyrocketed by 454,225bps to -856.97% in 2024, then spiked by 1,704,871bps to -1,770.82% in 2025.
  • Its EBITDA Margin stands at -1,770.82% for Q3 2025, versus -1,539.82% for Q2 2025 and -1,375.70% for Q1 2025.